← Human Trials & Peer-Reviewed Studies
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
Plain-language guide to PMID 38735641 (2024): observational study of Glucagon, diabetic retinopathy and glaucoma.
Key Facts
- PMID
- 38735641
- Journal
- Ophthalmology. Retina
- Year
- 2024
- Study type
- Observational Study
- Authors
- Barkmeier AJ et al. (10 authors)
- DOI
- 10.1016/j.oret.2024.05.003
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Glucagon in the context of diabetic retinopathy and glaucoma, published as an observational study.
To investigate whether the choice of glucose-lowering agent for type 2 diabetes (T2D) impacts a patient's risk of developing sight-threatening diabetic retinopathy complications.
Why It Was Studied
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Who Took Part
By PubMed's age tags, the people studied were adults, both men and women.
Adult (≥21 years) enrollees in United States commercial, Medicare Advantage, and Medicare fee-for-service plans from January 1, 2014, to December 31, 2021, with T2D and moderate cardiovascular disease (CVD) risk who had no baseline history of advanced diabetic retinal complications, initiating treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas.
How the Study Was Run
Retrospective observational database study emulating an idealized target trial.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents and Sodium-Glucose Transporter 2 Inhibitors.
The authors tagged it with the keywords Diabetic macular edema, GLP-1 RA, Proliferative diabetic retinopathy and SGLT2i.
What This Means in Plain Language
This is an observational study of Glucagon in people with diabetic retinopathy and glaucoma.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (Ophthalmology. Retina), a journal based in United States.
More context: the Glucagon compound page, Diabetic retinopathy and glaucoma research.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.